TCT-745 Guideline Based Referral for Septal Reduction Therapy In Patients With Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes: Longitudinal Follow-Up Of A Large, Single-Center Experience  by Kuttab, Johny S. et al.
B304 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5trial comparing ASA with SM have been performed. Furthermore, 3 of
the largest studies comparing the 2 procedures were published last
year. Hence, we performed an updated systematic review to compare
ASA and SM. Our primary aim was to compare the efﬁcacy of both
strategies in improving patient’s symptoms. Secondly, we wanted to
assess if there is any signiﬁcant difference in short and long term
mortality between the 2 approaches.
METHODS A comprehensive search strategy was designed and a thor-
ough computer based search was performed using OVID MEDLINE,
EMBASE and PubMed databases. No time limit to start date was applied
and the search was conducted up to 29 March 2015. We reviewed both
the identiﬁed manuscripts and references cited or citing indexed
studies. Of 1143 citations, 10 studies were included in the analysis.
RESULTS There were a total of 1824 patients with obstructive symp-
tomatic HCM of which 859 (44%) were treated with ASA and 1019 (56%)
with SM. Gender characteristics were available in 8 studies. Fifty-one
percent of patients in both of the groups were men (ASA¼349/677 and
SM¼367/721).The average follow-up in the ASA groupwas 2.9 2 years,
while SM patients were followed up for 4.5  4.4 years. Patients un-
dergoing SM were relatively younger (MD 6.3, 95% CI 3.06 to 9.55, p ¼
0.0001, I2 ¼ 73%) and had higher reduction in the LVOT gradient from
baseline ((MD -9.56, 95%CI -19.15 to 0.04, p¼0.05, I2¼ 95%). However,
there was similar resolution of class III and IV symptoms between the 2
groups (OR 1.21, 95% CI 0.29 to 5.14, p ¼ 0.56, I2 ¼ 0%) . There was no
difference in the sudden cardiac death (SCD) (OR 1.04 95% CI 0.44 –
2.48, p ¼ 0.93, I2 ¼ 0%), short-term (p ¼ 0.36), long-term all cause (OR
0.76 95%CI 0.47 – 1.24, p ¼ 0.27, I2 ¼ 28%) and long-term cardiac mor-
tality (OR 0.74 95% CI 0.26 – 2.14, p ¼ 0.58, I2 ¼ 63%). Patients under-
going ASA had higher incidence of post procedure pacemaker implant
(OR 3.09 95% CI 1.89 – 5.07, p < 0.00001, I2 ¼ 11%) and a repeat proce-
dure (OR 5.68 95% CI 2.59 – 12.47, p < 0.0001, I2 ¼ 0%).
CONCLUSIONS In conclusion, ASA and SM are equally effective to
resolve LVOTO related symptoms in patients diagnosed with HCM.
There is no difference in the early and late mortality between the 2
procedures. Neither there is any difference in the events of SCD. ASA
is less invasive but comes at the cost of higher requirement of pace-
maker implant because of conduction abnormalities post procedure.
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BACKGROUND Alcohol septal ablation (ASA) and surgical myectomy
are invasive treatment options available to patients with drug-re-
fractory, obstructive, hypertrophic cardiomyopathy (HCM). Expert
consensus guidelines recommend myectomy as the ﬁrst line option,
with ASA available for patients at high surgical risk or due to patient
preference. However, there is a paucity of data describing clinical
outcomes following a guideline-based strategy when assessing pa-
tients for invasive septal reduction therapy.
METHODS We sought to deﬁne long-term outcome in HCM patients
undergoing myectomy or ASA in a large HCM referral center, where
management recommendations have been based on 2003 ACC/ESC
and 2011 ACCF/AHA consensus guidelines. Clinical outcomes were
analyzed in 258 consecutive patients who underwent myectomy or
ASA between 2004 and 2012, over a mean follow-up of 4.0  2.2 years.
RESULTS Of the 258 patients, 207 (80%) were referred for myectomy
and 51 (20%) for ASA (40 because of perceived high-risk substrate and 11
due to personal preference). There were no differences at baseline be-
tween the two groups with respect to numerous co-morbidities (COPD,
CVA, diabetes, CKD, liver disease, and metastatic cancer), however,
when compared tomyectomypatients, ASApatientswere older (64 10
vs. 51  15 years; p <0.001), more commonly female (57% vs 41%;
p¼0.06), and had a higher risk score using the modiﬁed Charlson Score
index (3.4  1.4 vs. 2.3  1.4; p<0.001). Compared to ASA, patients who
underwent myectomy achieved a greater improvement in heart failure
symptoms compared to ASA (class I: 58% vs. 33%; p ¼0.003), while the
repeat procedure rate was more common after ASA (0.5% vs. 8%;
p ¼0.006). During follow-up there were 12 deaths, including 10 in pa-
tients who underwent myectomy and 2 following ASA. All-cause mor-
tality was 1.1%/year (0.9%/yr in ASA vs. 1.4%/yr in myectomy patients;p¼0.6) which did not differ when compared with age and gender-
matched US population (p¼0.8) (Figure).
CONCLUSIONS Guideline-based referral for septal reduction therapy
in drug-refractory HCM patients is associated with low mortality rates
for both ASA and myectomy, although there was greater improvement
in limiting heart failure symptoms in the younger, lower-risk myec-
tomy patients. These data substantiate a strategy of decision-making
for invasive septal reduction therapy based on the current expert
consensus guidelines.
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BACKGROUND Many studies have evaluated the safety and efﬁcacy
of alcohol septal ablation (ASA) in symptomatic patients with hyper-
trophic obstructive cardiomyopathy (HOCM), although there are still
no randomised trials, transcatheter ASA is a viable alternative for
patients with HOCM.
METHODS From2009 to 2015 89ASAperformed in 86patients (58males,
28 females)withHOCMatour center.Meanageof pts.was43 [6;76] years.
Temporary pacemaker lead was placed through a femoral or jugular
venous sheath in the right ventricular apex before ASA, also all pts. un-
dergone myocardial contrast echocardiography (MCE) before procedure.
Mean peak pressure gradient (PG) on LVOTwas 93,48,2 mm. Hg. Mitral
valve regurgitation (MR) more than moderate was in all pts. Mean
interventricular septum thickness was 2,5cm [1,6; 3,3].
RESULTS Mean PG on LVOT decreased from 93,48,2 mmHg to
35,34,6 mmHg. The grade of MR reduced from at least moderate to
mild or even trivial. In 3 cases was recorded the complete disap-
pearance of MR. The procedure – related mortality was 0%. In 2 cases
(2,3%) the procedure was aborted by the coronary angiography and
MCE data. Mean follow-up for 86pts (100%) was 684,1 months.
71(83%) pts had PG reduction (to 30 mmHg) – regarded as good result
of procedure. 11 (12,4%) pts had PG > 30mmHg, but signiﬁcant
improvement in symptoms. 1(1,1%) case of sudden death 6 mounts
after procedure. 3(3,5%) pts needed redo procedure due to residual
LVOTO. All redo pts had effective systolic PG decreasing after second
procedure. 6(6,7%) patients had complete AV block and required
